You have tried ashwagandha. Maybe from a reputable brand. Maybe from a practitioner. Maybe from the supplement aisle at a grocery store. And maybe it did something, or maybe it did nothing particularly noticeable, and you filed it away in the category of things that are probably fine but not life-changing.
If that is your experience, there is a real chance the ashwagandha you tried was genuinely different from the one in REVHORA — not in name, but in what it actually is and how it was made.
What standardization means — and why most labels skip past it
The ashwagandha category is dominated by commodity ingredient. When a supplement brand includes "ashwagandha root extract 300 mg" on a label, what they are typically using is a bulk powder sourced from a generic supplier, with unspecified withanolide content, no verified manufacturing process, and no research conducted on that specific preparation.
Withanolides are the primary bioactive compounds in ashwagandha — the compounds that the published research on ashwagandha's effects has been conducted on. The withanolide content of ashwagandha root varies significantly depending on the plant, the growing conditions, the part of the plant used, the extraction method, and whether any post-processing has occurred.
A label that says "ashwagandha extract" tells you almost nothing about withanolide content. A label that says "standardized to 5% withanolides" tells you something — but that percentage refers to the total extract, and the specific withanolides present, their bioavailability, and whether the extraction method preserves their activity is still unspecified.
This is not a technicality. If the research that suggests ashwagandha may support stress resilience, sleep quality, and nervous system regulation was conducted on a preparation with a specific withanolide profile and a specific extraction process, then the results of that research do not automatically transfer to a commodity powder with a different profile.
When someone says "I tried ashwagandha and it didn't do much," that experience is real — but it may not tell you whether ashwagandha can work. It may only tell you that the specific preparation they used wasn't characterized the same way the research was.
What Prolanza is
Prolanza is a specific, standardized form of ashwagandha developed with a sustained-release delivery mechanism. It is a named, characterized ingredient — which means it has a defined withanolide profile, a defined manufacturing process, and a supply chain that produces a consistent preparation.
The sustained-release aspect is important and worth explaining clearly.
Most botanical extracts are released from a supplement within a short window after ingestion. Peak concentration occurs relatively quickly, followed by a decline. For ashwagandha, which is intended to support baseline nervous system regulation over the course of a day — not to produce a sharp, temporary effect — this means most of the dose may be metabolized before the afternoon, when many women experience the stress peaks that matter most to them.
A sustained-release preparation is designed to extend the release of the active compounds over a longer period. The goal is not to amplify peak concentration, but to maintain meaningful circulating levels across a wider time window. For an adaptogen designed to support the body's stress-response system through the sustained demands of a full day — not just the first two hours of the morning — this is a meaningful formulation difference.
The withanolide difference in practice
Withanolides interact with the HPA axis — the hypothalamic-pituitary-adrenal axis that governs the stress-response cascade. The research examining ashwagandha's potential to support this system has consistently used standardized preparations, and the outcomes that have been reported in studies — related to perceived stress, measures of cortisol over time, sleep quality, and energy levels — are outcomes associated with the preparations that were studied.
REVHORA uses Prolanza at 150 mg in both AM and PM formulas. This is a dose that reflects the sustained-release mechanism — it is a lower absolute dose than many commodity products use, precisely because a sustained-release preparation delivers its active compounds over a longer window, rather than all at once.
For comparison: a generic product using 600 mg of commodity ashwagandha powder is not necessarily delivering more withanolide activity than 150 mg of Prolanza. It may be delivering less, if the commodity source has lower withanolide content and no sustained-release mechanism. The milligram number on the label is not the useful unit of comparison. The unit of comparison is the characterized bioactive content and the delivery profile.
What Prolanza ashwagandha may support — conservatively stated
Based on the research examining standardized ashwagandha preparations more broadly, Prolanza ashwagandha may support:
- The body's adaptive response to everyday stress
- Nervous system calmness without sedation
- Sleep quality, particularly restorative sleep
- A steadier energy baseline across the day
These are not guarantees. Individual biology, stress load, nutritional status, sleep patterns, and many other factors influence how any adaptogen is experienced. The research on ashwagandha does not show that it works uniformly in every person, and REVHORA will not claim that it does.
What the research does suggest — consistently, across multiple standardized preparations — is that ashwagandha at a meaningful dose of a characterized extract, taken consistently over four to eight weeks, is associated with meaningful outcomes in these domains for a substantial proportion of the people studied.
If that has not been your experience with ashwagandha before, the formulation difference may be a relevant variable. Not a guarantee — a variable worth considering.
The skepticism is appropriate
If you are skeptical of ashwagandha because of past experience, that skepticism is reasonable. The supplement market has given it to you in forms and doses that may bear little relationship to what the research used. It has been added to energy drinks, included in skin care products, offered as a 50 mg afterthought in generic stress blends.
Ashwagandha that is standardized, characterized, and delivered in a form designed for sustained activity is a different thing. It is an ingredient that a formulator had to seek out, specify, and pay more to include — not an ingredient sourced by default.
That distinction between deliberate formulation and label appeal is worth caring about. When you are taking something every day as part of a ritual that is meant to compound over weeks, the specificity of what you are actually taking matters.
Why it is in both formulas
Ashwagandha appears in both Hormonal Balance AM and Menopause Support PM, at the same 150 mg Prolanza dose, because the stress-response system is relevant to both life stages these formulas address.
For Maya navigating a full professional life with underlying hormonal and metabolic shifts, the HPA axis is a central player in how her hormonal system is functioning day to day. Supporting its regulatory capacity is relevant to cycle rhythm, mood, cravings, and the ability to sustain a consistent morning ritual.
For Diana navigating the menopausal transition, the stress-response overlay on top of the estrogen-transition process often compounds what are already significant physiological changes. Supporting nervous system regulation is not a secondary concern in menopause support — it is part of the core mechanism.
In both cases, Prolanza at 150 mg — consistent, sustained-release, standardized — is there to support the adaptive capacity of the system that influences both formulas' primary outcomes.
That is formulation logic, not marketing logic. And it is a distinction that is visible once you know what to look for.